New heart pump may reduce death and stroke in risky surgeries
NCT ID NCT05756751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the Impella 5.5 heart pump in 123 high-risk patients with weak hearts (ejection fraction 25% or less) who need complex cardiac surgery. The pump supports the heart during and after surgery to prevent failure, stroke, and other complications. The goal is to confirm the device's safety and effectiveness in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
123 people
The number who actually took part.
- Started
-
Apr 2023
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Hemodynamically stable patients undergoing one (1) of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest * Isolated CABG * Isolated mitral valve repair or replacement (MVR) * Isolated aortic valve repair or replacement (AVR) * At lest two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR) 2. LVEF within 30 days before surgery of either: * ≤25% measured by echocardiogram or * LVEF ≤35% as above for patients with significant mitral regurgitation (MR 3+ or 4+; see definition) and planned corrective mitral valve surgery (including MV replacement or repair) 3. Age 18 years or older 4. Subject has signed informed consent form and is willing and able to attend all follow-up visits and to perform all tests. 5. Patient is eligible to receive the Impella 5.5 as per the current IFU. Exclusion Criteria: 1. Salvage operation (cardiac arrest within 24 hours prior to index surgery) 2. Unresponsive state within 24 hours of the time of surgery 3. Any inotrope within 72 hours of surgery 4. Any mechanical MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place prior to informed consent 5. RV dysfunction requiring mechanical or inotropic support preoperatively and/or likely to be needed postoperatively 6. Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy 7. Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return 8. Ventricular septal defect (VSD) 9. Stroke within 30 days of the index cardiac surgical procedure 10. Prior mantle field chest irradiation 11. Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD 12. History of chronic dialysis 13. Pre-existing liver dysfunction defined as Child-Pugh Class B or C 14. Pre-existing pulmonary disease requiring home oxygen, or "severe pulmonary disease" determined by enrolling investigator 15. Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis) 16. Confirmed COVID-19 infection within two (2) weeks prior to operation 17. Pregnant or planning pregnancy within next 12 months. NOTE: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to intervention. 18. Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint 19. Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions 20. Inability to perform aortic cross-clamp, such as due to porcelain aorta 21. Any contraindication or condition that would prevent the ability to place Impella 5.5® (per current IFU), including LV thrombus and/or presence of a mechanical aortic valve 22. Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which, could interfere with the conduct of the trial or that, in the opinion of the investigator would pose an unacceptable risk to the subject in the trial. 23. Subject has other medical, social or psychological problems that, in the opinion of the investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures, including patients under guardianship 24. Any subject considered to be part of a vulnerable population (as per ISO 14155)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Left ventricular dysfunction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Deutsches Herzzentrum der Charité
Berlin, 13353, Germany
-
IKEM Prague
Prague, 14021, Czechia
-
Krankenhaus der Barmherzigen Brüder Trier
Trier, 54292, Germany
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
-
RWTH Uniklinik Aachen - Klinik für Herzchirurgie
Aachen, North Rhine-Westphalia, 52074, Germany
-
UKSH Campus Kiel - Klinik für Herz- und Gefäßchirurgie
Kiel, Schleswig-Holstein, 24105, Germany
-
Universitäres Herz- und Gefäßzentrum Hamburg - Klinik und Poliklinik für Herz- und Gefäßchirurgie
Hamburg, 20246, Germany
-
Universitätsklinikum Düsseldorf, Klinik für Herzchirurgie
Düsseldorf, North Rhine-Westphalia, 40225, Germany
-
Universitätsklinikum Giessen
Giessen, 35392, Germany
-
Universitätsklinikum Heidelberg - Klinik für Herzchirurgie
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
Universitätsmedizin Essen, Westdeutsches Herzzentrum, Klinik für Thorax- und Kardiovaskuläre Medizin
Essen, North Rhine-Westphalia, 45147, Germany
-
Universitätsmedizin Halle/Saale - Klinik für Herzchirurgie
Halle, SA, 06120, Germany
-
Universitätsmedizin Mainz, Klinik und Poliklinik für Herz- und Gefäßchirurgie
Mainz, RLP, 55131, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wearable patches could spot heart danger hiding in cancer treatment
- Heart pump may boost survival in High-Risk surgery patients
- Heart stem cell trial pulled before it even started
- Heart valve repair may unlock higher doses of key heart failure drugs
- AI reads your Heart's future: new test spots cancer drug danger
- AI reads your Heart's electrical signals to predict failure years in advance